Partnering for progress: A decade of trust in Devyser CFTR
With the IVDR transition approaching, European clinical laboratories are preparing for changes that...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
With the IVDR transition approaching, European clinical laboratories are preparing for changes that...
Read More
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
Read More
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
Read More
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More